Eye mounted device for therapeutic agent release
US-12167978-B2 · Dec 17, 2024 · US
Pharmaceutical composition comprising a Vitamin E derivative and a cell death marker
US9539203B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9539203-B2 |
| Application number | US-80926208-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 19, 2008 |
| Priority date | Dec 19, 2007 |
| Publication date | Jan 10, 2017 |
| Grant date | Jan 10, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to a carrier for delivering agents to the posterior region of the eye, the carrier comprising a Vitamin E derivative, especially tocopherol. The carrier may also comprise a cell death marker, such as an annexin.
First claim
Opening claim text (preview).
The invention claimed is: 1. A pharmaceutical composition, comprising: a combination of a Vitamin E derivative and a cell death marker, wherein the cell death marker is annexin V or a functional fragment or derivative thereof that binds reversibly to cellular membranes in the presence of cations. 2. The pharmaceutical composition of claim 1 , wherein the Vitamin E derivative is a tocopherol or a derivative thereof. 3. The pharmaceutical composition of claim 2 , wherein the tocopherol is D-[alpha]-tocopherylsuccinate esterified to polyethyleneglycol 1000. 4. A method of delivering a cell death marker to a posterior segment of an eye, comprising: administering the pharmaceutical composition of claim 1 to the eye. 5. The method of claim 4 , wherein the Vitamin E derivative is D-[alpha]-tocopherylsuccinate esterified to polyethyleneglycol 1000. 6. The method of claim 4 , wherein the pharmaceutical composition is formulated for topical delivery. 7. The method of claim 4 , wherein the biologically or therapeutically active agent and pharmaceutical composition are delivered topically. 8. The method of claim 7 , wherein the Vitamin E derivative is D-[alpha]-tocopherylsuccinate esterified to polyethyleneglycol 1000. 9. The method of claim 4 further comprising delivering a neuroprotectant, a growth factor, a growth factor antagonist, an antibody, an aptamer, or a steroid to the eye. 10. The pharmaceutical composition of claim 1 , wherein the composition further comprises one or more additional components selected from physiological saline, bacteriostatic water, polyethoxylated castor oil, ethanol and polyol. 11. A pharmaceutical composition comprising a Vitamin E derivative; and a cell death marker, wherein the cell death marker is an annexin or functional fragment or derivative thereof that binds reversibly to cellular membranes in the presence of cations and wherein the Vitamin E derivative is D-[alpha]-tocopherylsuccinate esterified to polyethyleneglycol 1000. 12. The pharmaceutical composition of claim 11 , wherein the annexin is annexin V. 13. The pharmaceutical composition of claim 11 , wherein the composition further comprises one or more additional components selected from the physiological saline, bacteriostatic water, polyethoxylated castor oil, ethanol and polyol. 14. The pharmaceutical composition of claim 1 , wherein the composition further comprises phosphatidylserine and/or phosphatidylethanolamine. 15. The method of claim 9 wherein the neuroprotectant is memantine or the antibody is selected from ranibizumab and bevacizumab.
Assignees
Inventors
Classifications
Ophthalmic agents · CPC title
Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones · CPC title
- A61K9/0048Primary
Eye, e.g. artificial tears · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9539203B2 cover?
- The invention relates to a carrier for delivering agents to the posterior region of the eye, the carrier comprising a Vitamin E derivative, especially tocopherol. The carrier may also comprise a cell death marker, such as an annexin.
- Who is the assignee on this patent?
- Cordeiro Francesca, MOSS Stephen, Ucl Business Plc
- What technology area does this patent fall under?
- Primary CPC classification A61K9/0048. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).